Drug Profile
Phenylephrine extended-release
Alternative Names: Phenylephrine extended-release - Schering-Plough; Phenylephrine HCl extended-release; Phenylephrine hydrochloride extended-release; SCH-002063Latest Information Update: 09 Oct 2021
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Bayer
- Class Antihypotensives; Decongestants; Ethanolamines; Mydriatics; Phenethylamines; Skin disorder therapies; Small molecules; Urologics
- Mechanism of Action Alpha 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 31 Oct 2011 Bayer completes a phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)
- 20 Oct 2011 Merck Sharp & Dohme completes enrolment in its phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)